BFRIW — Biofrontera Inc. Warrants
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$0.03
-$0.00 (-2.07%)
Biofrontera Inc. Warrants (BFRIW) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Hermann Luebbert Ph.D., based in 120 Presidential Way, Woburn, MA, United States, 01801, with about 92 employees. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest reported BFRIW revenue for 2025-09-30 was $7.0M. Net income was -$6.6M. Revenue was down 22.6% from 2025-06-30 to 2025-09-30.
Use this BFRIW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BFRIW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BFRIW SEC filings page. Lician reads the product cache first so this HTML stays unique to Biofrontera Inc. Warrants even when a live quote feed is slow.
About Biofrontera Inc. Warrants
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRIW Key Statistics
Market Cap
$0.00M
Volume
156
Previous Close
$0.03
Day Range
$0.03 – $0.10
EPS
-$3.22
Revenue
$37.32M
Net Income
-$17.76M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+9.5%
Profit Margin
-47.6%
Employees
92
BFRIW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $37.32M | $34.07M | $28.67M | $24.10M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.76M | -$20.13M | -$640.00K | -$37.71M |
| EPS (Diluted) | -$3.22 | -$13.02 | -$0.61 | $0.00 |
Total Assets
$22.10M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.91M
Operating Cash Flow
-$10.27M
Free Cash Flow
$0.00
Biofrontera Inc. Warrants Company Information
- CEO, President & Chairman
- Hermann Luebbert Ph.D.
- Headquarters
- 120 Presidential Way, Woburn, MA, United States, 01801
- Website
- www.biofrontera-us.com
- Phone
- 781 245 1325
- IPO / Founded
- 2021-10-29
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic